Similar articles for PMID: 32591491

Year	Number of Results
1994	1
2004	1
2005	2
2007	2
2008	3
2009	3
2010	2
2011	1
2012	7
2013	8
2014	9
2015	11
2016	12
2017	8
2018	15
2019	13
2020	13
2021	8
2022	12
2023	3
2024	0

1

Dose-Effect Relationships of ¹⁶⁶Ho Radioembolization in Colorectal Cancer.

van Roekel C, Bastiaannet R, Smits MLJ, Bruijnen RC, Braat AJAT, de Jong HWAM, Elias SG, Lam MGEH. van Roekel C, et al. J Nucl Med. 2021 Feb;62(2):272-279. doi: 10.2967/jnumed.120.243832. Epub 2020 Jun 26. J Nucl Med. 2021. PMID: 32591491 Free article.

2

First Evidence for a Dose-Response Relationship in Patients Treated with ¹⁶⁶Ho Radioembolization: A Prospective Study.

Bastiaannet R, van Roekel C, Smits MLJ, Elias SG, van Amsterdam WAC, Doan D, Prince JF, Bruijnen RCG, de Jong HWAM, Lam MGEH. Bastiaannet R, et al. J Nucl Med. 2020 Apr;61(4):608-612. doi: 10.2967/jnumed.119.232751. Epub 2019 Oct 10. J Nucl Med. 2020. PMID: 31601696 Free article. Clinical Trial.

3

(⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.

Elschot M, Nijsen JF, Lam MG, Smits ML, Prince JF, Viergever MA, van den Bosch MA, Zonnenberg BA, de Jong HW. Elschot M, et al. Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1965-75. doi: 10.1007/s00259-014-2784-9. Epub 2014 May 13. Eur J Nucl Med Mol Imaging. 2014. PMID: 24819055 Clinical Trial.

4

Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.

Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Mali WP, van Het Schip AD, Zonnenberg BA. Smits ML, et al. Lancet Oncol. 2012 Oct;13(10):1025-34. doi: 10.1016/S1470-2045(12)70334-0. Epub 2012 Aug 22. Lancet Oncol. 2012. PMID: 22920685 Clinical Trial.

5

Dose-Response and Dose-Toxicity Relationships for Glass ⁹⁰Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer.

Alsultan AA, van Roekel C, Barentsz MW, Smits MLJ, Kunnen B, Koopman M, Braat AJAT, Bruijnen RCG, de Keizer B, Lam MGEH. Alsultan AA, et al. J Nucl Med. 2021 Nov;62(11):1616-1623. doi: 10.2967/jnumed.120.255745. Epub 2021 Mar 19. J Nucl Med. 2021. PMID: 33741643 Free PMC article.

6

Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.

van den Hoven AF, Rosenbaum CE, Elias SG, de Jong HW, Koopman M, Verkooijen HM, Alavi A, van den Bosch MA, Lam MG. van den Hoven AF, et al. J Nucl Med. 2016 Jul;57(7):1014-9. doi: 10.2967/jnumed.115.166942. Epub 2016 Feb 23. J Nucl Med. 2016. PMID: 26912436 Free article. Clinical Trial.

7

Efficacy of Radioembolization with ¹⁶⁶Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study.

Prince JF, van den Bosch MAAJ, Nijsen JFW, Smits MLJ, van den Hoven AF, Nikolakopoulos S, Wessels FJ, Bruijnen RCG, Braat MNGJA, Zonnenberg BA, Lam MGEH. Prince JF, et al. J Nucl Med. 2018 Apr;59(4):582-588. doi: 10.2967/jnumed.117.197194. Epub 2017 Sep 15. J Nucl Med. 2018. PMID: 28916623 Free article. Clinical Trial.

8

Additional hepatic ¹⁶⁶Ho-radioembolization in patients with neuroendocrine tumours treated with ¹⁷⁷Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial).

Braat AJAT, Kwekkeboom DJ, Kam BLR, Teunissen JJM, de Herder WW, Dreijerink KMA, van Rooij R, Krijger GC, de Jong HWAM, van den Bosch MAAJ, Lam MGEH. Braat AJAT, et al. BMC Gastroenterol. 2018 Jun 15;18(1):84. doi: 10.1186/s12876-018-0817-8. BMC Gastroenterol. 2018. PMID: 29902988 Free PMC article. Clinical Trial.

9

Surefire infusion system versus standard microcatheter use during holmium-166 radioembolization: study protocol for a randomized controlled trial.

van den Hoven AF, Prince JF, Bruijnen RC, Verkooijen HM, Krijger GC, Lam MG, van den Bosch MA. van den Hoven AF, et al. Trials. 2016 Oct 25;17(1):520. doi: 10.1186/s13063-016-1643-3. Trials. 2016. PMID: 27782851 Free PMC article. Clinical Trial.

10

Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with ⁹⁰Y in the SARAH Study.

Hermann AL, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V; SARAH Trial Group. Hermann AL, et al. Radiology. 2020 Sep;296(3):673-684. doi: 10.1148/radiol.2020191606. Epub 2020 Jun 30. Radiology. 2020. PMID: 32602828

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

112 results

Results by year